Get the app
US › Healthcare

Dogwood Therapeutics, Inc. (DWTX)

US · Healthcare · Biotechnology

$1.72+1.18%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit
$-11.5M
EPS
$-0.34
EPS estimate
$-0.13

EPS came in at -0.34 against a street estimate of -0.13 — a miss of 161.5%.

Key statistics

Market cap
$58.8M
P/E
1.0
Forward P/E
0.0
P/B
0.90
Book value
$2.03
EPS (TTM)
$1.81
52-week high
$9.50
52-week low
$1.28
50-day MA
$1.88
200-day MA
$2.61
Beta
1.83

Analyst view

Analysts rate Dogwood Therapeutics, Inc. a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $14.00.

Shareholding

Insiders
72.57%
Institutions
11.47%

Largest institutional holders

FundStake
Armistice Capital, LLC9.75%
Millennium Management LLC1.02%
Vanguard Capital Management, LLC0.39%
Geode Capital Management, LLC0.24%
Vanguard Fiduciary Trust Co0.19%
Northern Trust Corp0.07%
The Goldman Sachs Group Inc0.04%
Marshall Wace Asset Management Ltd0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dogwood Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.